Edition:
India

BeiGene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

93.60USD
15 Dec 2017
Change (% chg)

$-0.27 (-0.29%)
Prev Close
$93.87
Open
$94.64
Day's High
$94.93
Day's Low
$92.20
Volume
270,604
Avg. Vol
123,214
52-wk High
$118.71
52-wk Low
$27.94

Chart for

About

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290... (more)

Overall

Beta: --
Market Cap(Mil.): $4,400.80
Shares Outstanding(Mil.): 3.26
Dividend: --
Yield (%): --

Financials

BRIEF-Beigene expands global pivotal program for BTK inhibitor BGB-3111

* Beigene expands global pivotal program for BTK inhibitor BGB-3111

14 Nov 2017

BRIEF-Beigene Ltd qtrly ‍net income attributable to common shareholders per ADS, diluted $2.54​

* Beigene Ltd - qtrly ‍net income attributable to common shareholders per ads, diluted $2.54​ Source text for Eikon: Further company coverage:

14 Nov 2017

China biotech's 'coming out party' masks long road ahead

LONDON/SHANGHAI Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.

19 Oct 2017

China biotech's 'coming out party' masks long road ahead

LONDON/SHANGHAI Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.

19 Oct 2017

INSIGHT-China biotech's 'coming out party' masks long road ahead

LONDON/SHANGHAI, Oct 19 Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.

19 Oct 2017

Breakingviews - China's drugmakers boast Big Pharma option value

HONG KONG (Reuters Breakingviews) - China's drug companies could provide a boost to Big Pharma. This week’s New York initial public offering of Shanghai-based Zai Lab highlights a new breed of innovative eastern drug makers specializing in treatments made from living cells known as biologics. They are eyeing a slice of the $1 trillion-plus global medicine market.

18 Sep 2017

BRIEF-Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​

* Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​ Source text : (http://bit.ly/2guND0F) Further company coverage:

01 Sep 2017

BRIEF-Beigene prices 2.46 mln ADS at $71 per unit

* Pricing of its follow-on public offering of 2,465,000 american depositary shares at a price to public of $71.00 per ads Source text for Eikon: Further company coverage:

11 Aug 2017

BRIEF-Beigene announces proposed public offering

* Beigene Ltd - ‍announced a public offering of adss each representing 13 of its ordinary shares, par value $0.0001 per share​

10 Aug 2017

Celgene signs deal with BeiGene for tumor cancer treatment

Celgene Corp said it would buy a stake in BeiGene Ltd to help develop and commercialize the China-based cancer immunotherapy developer's treatment for solid tumor cancers, expanding its position in the field of immuno-oncology.

06 Jul 2017

Earnings vs. Estimates